<DOC>
	<DOCNO>NCT02872961</DOCNO>
	<brief_summary>PURPOSE : This study evaluate relationship small intestinal bacterial overgrowth ( SIBO ) , immune activation , inflammation , symptom pediatric abdominal pain-related functional gastrointestinal disorder ( FGIDs ) , i.e. , irritable bowel syndrome ( IBS ) , functional dyspepsia ( FD ) , &amp; functional abdominal pain ( FAP ) , good understand role SIBO pathogenesis . DESIGN &amp; PROCEDURES : Cross-sectional study . Subjects : Patients follow UT-Houston Pediatric GI clinic , age 4-17 year , undergo endoscopic evaluation abdominal pain , meet Rome III diagnostic criterion IBS , FD , FAP , without evidence organic etiology abdominal pain upon routine laboratory , radiologic , endoscopic , histologic evaluation . Sample Size : At least 30 patient , ≥ 15 SIBO ( i.e. , positive small bowel aspirate culture and/or glucose breath hydrogen test ) , ≥15 without SIBO . Sample Materials : Small bowel biopsy aspirate , serum , breath sample , symptom questionnaire response . Measures : 1 ) Immune activation &amp; inflammation - measure serum cytokine level &amp; small intestinal tissue inflammatory cell infiltration &amp; cytokine level . 2 ) Symptoms - measure Abdominal Pain Index , Wong-Baker FACES™ Pain Rating Scale , Questionnaire Pediatric Gastrointestinal Symptoms - Rome III Version . 3 ) Small bowel microbiota analysis - assess 454 pyrosequencing . RISKS &amp; POTENTIAL BENEFITS : Aside risk associate routine endoscopy biopsy , would occur even without study enrollment , risk associate serum collection , one extra biopsy specimen collection , small bowel aspirate collection , completion pain scales/ questionnaire , glucose breath hydrogen test purpose study minimal . POTENTIAL IMPACT : This study yield valuable information regard relationship SIBO , immune activation , inflammation , symptom pediatric IBS , FD , FAP . Potential biomarkers support diagnosis FGIDs novel target therapy , immune molecule previously unrecognized bacterial phylotypes specie possibly contribute disease pathogenesis , may identify . Also , determine reliability glucose breath hydrogen test vs. small bowel aspirate culture diagnosis SIBO setting may enable physician avoid invasive costly procedure diagnostic work-up child FGIDs .</brief_summary>
	<brief_title>SIBO , Immune Activation , FGIDs Children</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>1 . Pediatric patient , age 417 year , upon initial evaluation abdominal pain . 2 . Complaints abdominal pain least 2 month upon entry study . 3 . Esophagogastroduodenoscopy ( EGD ) order patient 's gastroenterologist evaluation / workup patient 's abdominal pain . 4 . Fulfillment Rome III criterion child/adolescent abdominal painrelated functional gastrointestinal disorder study ( i.e. , irritable bowel syndrome , functional dyspepsia , functional abdominal pain ) . 5 . Signed informed consent subject 's participation study provide parent / legal guardian ; sign assent sign study participant 8 year old . History short bowel syndrome , define clinically significant malabsorption result surgical resection substantial portion ( ≥ 50 % ) small intestine , complete dysfunction extensive portion ( ≥ 50 % ) small bowel . 2 . History gastrointestinal surgery ( except appendectomy ) . 3 . Other know suspected motility disorder achalasia , gastroparesis , chronic intestinal pseudoobstruction , dump syndrome , Hirschprung 's disease , neuromuscular disease . 4 . Evidence enteric infection infestation laboratory screen mucosal biopsy . 5 . Known suspected liver , renal , pancreatic disease . 6 . Diabetes mellitus , systemic lupus erythematosus , and/or systemic disease . 7 . Use antibiotic , mast cell stabilizer , leukotriene modifier , and/or systemic steroid within 2 week precede small bowel aspirate culture biopsy ; use antibiotic probiotic within 2 week glucose breath hydrogen test . 8 . Use opiates benzodiazepine ( aside give anesthesia purpose endoscopy procedure ) laxatives ( aside give bowel preparation endoscopy procedure ) within 1 week precede small bowel aspirate culture and/ glucose breath hydrogen test . 9 . Acute infection acute inflammatory process ( e.g. , upper respiratory tract infection , pneumonia , urinary tract infection , gastroenteritis , pancreatitis , etc . ) within 2 week precede serum sample mucosal biopsy collection . 10 . Symptomatic atopic disorder ( i.e. , eczema , allergic rhinitis , asthma ) within 2 week precede serum collection study . 11 . Any evidence inflammatory bowel disease , celiac disease , H. pylorus infection , eosinophilic esophagitis , giardiasis , potential organic etiology abdominal pain upon endoscopic / histologic evaluation . 12 . Cancellation endoscopy procedure subject 's gastroenterologist , parent , and/ legal guardian .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>